Tarsus Pharmaceuticals (TARS) Cash from Operations (2019 - 2026)

Tarsus Pharmaceuticals' Cash from Operations history runs 8 years deep, the most recent figure standing at 24652000.0 for Q1 2026.

• In Q1 2026, Cash from Operations fell 19.37% year-over-year to 24652000.0; the TTM figure through Mar 2026 stood at 16452000.0 (up 75.03% YoY), while the FY2025 annual figure was 12451000.0, up 85.0% from the prior year.
• Cash from Operations for Q1 2026 stood at 24652000.0, down from 19330000.0 in the prior quarter.
• The five-year high for Cash from Operations was 19330000.0 in Q4 2025, with the low at 39335000.0 in Q4 2023.
• The 5-year median for Cash from Operations is 20651000.0 (2025), against an average of 16861941.18.
• The sharpest annual moves came in 2023 and 2025: Cash from Operations plunged 459.43% in 2023, then soared 311.01% in 2025.
• Tarsus Pharmaceuticals' Cash from Operations stood at 10874000.0 in 2022, then sank by 261.73% to 39335000.0 in 2023, then surged by 43.61% to 22182000.0 in 2024, then jumped by 187.14% to 19330000.0 in 2025, then plunged by 227.53% to 24652000.0 in 2026.
• Business Quant data shows TARS's Cash from Operations at 24652000.0 in Q1 2026, 19330000.0 in Q4 2025, and 18257000.0 in Q3 2025.